Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Launches Ground-Breaking 58-Gene Tumour Profiling Service

Published: Tuesday, May 28, 2013
Last Updated: Tuesday, May 28, 2013
Bookmark and Share
This Technology Strategy Board-funded, government-backed assay performs significantly better than standard tests.

Oxford Gene Technology (OGT) has furthered its commitment to fighting cancer with the launch of a new solid tumour profiling next-generation sequencing service to advance vital research into personalised cancer care. OGT is the first commercial facility in the UK to offer this service.

OGT’s SureSeq™ Solid Tumour Panel Sequencing Service profiles the mutations of patient tumours for 58 cancer-associated genes prioritised by Cancer Research UK and leading cancer researchers. The genes include those important in breast, prostate, ovarian, lung and colorectal cancers, many with currently actionable mutations.  OGT also offers researchers the flexibility to further customise the panel by adding additional genes of interest.

The panel of 58 genes was developed in collaboration with researchers at the Salisbury and Birmingham NHS Regional Genetics Laboratories as part of a £1.16 million funding award from the UK Government-backed Technology Strategy Board’s Stratified Medicines programme. The ultimate aim of the programme is to improve patient care and achieve significant cost savings over the single gene tests currently available. OGT has applied its extensive expertise in probe design to Agilent’s industry-leading SureSelect™ hybridisation methodology, to deliver an assay with unparalleled uniformity of targeted sequence enrichment, excellent accuracy and sensitivity of variant detection across full genes, and robust performance with FFPE samples. All results are delivered in a comprehensive interactive web-based report to enable informed interpretation of results.

Dr Mike Evans, CEO at OGT said: “We are committed to tackling cancer by developing tools for cancer research, such as biomarkers for early detection and tumour profiling assays, such as SureSeq. This comprehensive, full-gene assay allows clinical researchers to accurately identify known and de novo mutations, enabling the development of informed, personalised cancer treatment strategies. We are proud to be working alongside the Technology Strategy Board and NHS in order to revolutionise cancer profiling and treatment.”

The project partners, including Salisbury and Birmingham NHS Regional Genetics Laboratories, validated the tumour profiling assay with fresh, frozen and formalin-fixed, paraffin-embedded (FFPE) samples. In a blind study of previously genotyped clinical samples, the assay accurately detected all variants present. Through expert probe design by OGT and improved uniformity of sequence enrichment, the assay also delivered an improved likelihood of variant discovery across all regions of the genes, enabling the detection of low-frequency somatic variants in heterogeneous cancer samples.

Dr Alasdair Gaw, Lead Technologist, Stratified Medicine at the UK’s innovation agency, the Technology Strategy Board said: “We are pleased with the progress made by OGT and its partners in the development of this new tumour profiling assay. We are confident that the implementation of such assays will significantly advance our understanding of cancer, enabling stratified medicine and the development of personalised cancer treatment regimes that will significantly improve patient care.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Announces Commercial and Financial Highlights for FY 2015
New products launched across all core brands; Cytocell® FISH, SureSeq™ NGS and CytoSure™ arrays for cancer and rare disease.
Saturday, December 12, 2015
OGT Licenses SNP Probe Technology to BMGL
Proprietary technology allows superior LOH detection in challenging samples.
Friday, November 13, 2015
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
New Whitepaper Compares Targeted Resequencing Strategies
OGT provides insight into choice of NGS methods.
Wednesday, July 17, 2013
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!